ARTIDIS

We’re excited to participate in #RSNA2025, the world’s leading radiology forum, where the latest ideas shaping the future of imaging and diagnostics come together. What we bring: the ARTIDIS, an investigational nanomechanical phenotyping platform. Our goal is to enable ARTIDIS® to be used at the time of the first biopsy, within the established radiology workflow, prior to downstream analysis. By aligning with established radiology processes, we hope to support radiologists at the very start of the patient journey, offering new layers of insight. If you’ll be at Radiological Society of North America (RSNA) 2025, we’d welcome the chance to connect, we’d love to hear your perspective on how nanomechanical diagnostics could complement traditional imaging. Visit our booth and talk to our team members Marija Plodinec Philipp Oertle Ahmed Jizawi Tobias A. Appenzeller Julia Ortega, DMSc, MHS, PA Carolina Ortiz Velez Anneke Geyer 📍 Location: McCormick Place, Chicago 🔹 Booth: #3947 📅 Dates: November 30 – December 4, 2025

Today on World Pancreatic Cancer Day, we stand with the patients, families, and clinicians facing one of the most challenging and aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited treatment options. Despite advances in surgery, chemotherapy, and targeted therapies, recurrence and treatment resistance are still major obstacles. At ARTIDIS, we are committed to advancing earlier and more precise insights that can change the standard of care in the future: 🔹 Identify early-stage patients - Delivering within a few hours biopsy readouts through real-time biomechanical analysis, helping clinicians avoid delays in critical decision-making. 🔹 Stratify early-stage patients - Using biophysical cell signatures to identify which patients are at risk for metastasis, guiding urgent intervention. 🔹 Treat appropriately and smarter - Leveraging mechanical and biophysical fingerprints to support more precise, patient-specific first-line therapy choices. Our ongoing pilot study in pancreatic cancer explores the nanomechanical properties of PDAC to identify signatures that may serve as novel biomarkers, helping optimize therapeutic strategies and improve patient outcomes. We also recognize important efforts across the field, such as the EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease), a randomized phase III study evaluating whether metastasis-directed therapy (MDT) to all disease sites can improve progression-free survival (PFS) and overall survival (OS) compared to systemic therapy alone, along with safety and treatment-outcome assessments. Studies like EXPAND underscore the need for treatment strategies that are more personalized and guided by deeper tumor insights. Read more here https://lnkd.in/etN8kRWk #WorldPancreaticCancerDay #PancreaticCancer #CancerAwareness #EarlyDetection #PatientCare #ARTIDIS Marija Plodinec Marko Loparic Tobias A. Appenzeller Ahmed Jizawi Philipp Oertle

How much can the physical properties of a tumor reveal? Advocates for Collaborative Education are bringing this conversation to the forefront with an expert panel featuring Dr. Marija Plodinec, CEO of ARTIDIS, together with Allison Rosen, MS, Steven Merlin, Stacey Tinianov, MPH, BCPA, Dr. Wendy Woodward and Dr. Simona Shaitelman. The discussion will explore how biophysical measurements of solid tumors are reshaping clinical decision-making and expanding what is possible in the diagnostics ecosystem an area central to ARTIDIS' mission and innovation. #PatientAdvocacy #CancerAdvocates #PatientCenteredCare #OncologyAwareness #CollaborationInCare #ARTIDIS Marija Plodinec Marko Loparic Tobias A. Appenzeller Ahmed Jizawi Philipp Oertle

How can collaboration advance whole-person care for patients with pancreatic cancer? Marija Plodinec, PhD, CEO of ARTIDIS, and Julia Ortega, DMSc, MHS, PA, Head of Clinical Operations (USA), recently participated in the 2025 Canopy Cancer Collective Learning Session, at UT Southwestern Medical Center in Dallas, Texas. This event brought together leaders in oncology and care delivery to advance the RightTrack aim, improving treatment decisions and supporting whole-person care for patients with pancreatic cancer. ARTIDIS is proud to contribute to this mission by providing innovative technology that supports clinicians and researchers in developing more personalized, precise, and compassionate approaches to cancer care. Many thanks to Carrie Tompkins Stricker, PhD, RN, ANP-BC, and the Canopy Cancer Collective team for fostering collaboration and driving progress in this important field. #CanopyCancerCollective #PancreaticCancer #Oncology #Artidis #PrecisionMedicine #Collaboration #CancerResearch Marija Plodinec Marko Loparic Ahmed Jizawi Tobias A. Appenzeller Philipp Oertle

How can we accelerate precision in immuno-oncology through science and technology?   At the Society for Immunotherapy of Cancer (SITC), experts highlighted advances in tumor immunology, novel biomarkers, and next-generation therapies from bispecific antibodies to in-vivo CAR-T cells, all aiming to refine how we target and monitor the immune response in cancer.   At ARTIDIS, we share this scientific perspective through research at the nanoscale. Our nanomechanical phenotyping platform enables quantitative measurement of the physical properties of cancer cells and their microenvironment, uncovering biomechanical patterns associated with tumor behavior and treatment response in preclinical and translational studies. When integrated with ARTIDISNET analytics, these multidimensional datasets contribute to deeper biological insights and data-driven hypothesis generation. By bridging nanotechnology, data science, and translational oncology research, ARTIDIS is helping to expand the frontier of precision cancer research—starting from the very first interaction with a biopsy sample. #ImmunoOncology #SITCS2025 #CancerResearch #PrecisionMedicine #AI #ARTIDIS Marija Plodinec Marko Loparic Ahmed Jizawi Tobias A. Appenzeller Anneke Geyer Philipp Oertle Julia Ortega, DMSc, MHS, PA Jacqueline Tilley, MSc. Celeste Manfredonia, PhD Franziska Lisa Lampart Carolina Ortiz Velez

Kicking off the Society for Immunotherapy of Cancer (SITC) Annual Meeting! The ARTIDIS team is excited to be at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, taking place at the Gaylord National Resort and Convention Center, National Harbor, Maryland. 📍 Visit us at Booth #731 to meet our team and management: Ahmed Jizawi (Head of Device Operations), Julia Ortega, DMSc, MHS, PA (Head of Clinical Operations, US), and our Product Champions Franziska Lisa Lampart, PhD, Celeste Manfredonia, PhD, Jacqueline Tilley, MSc. and Marketing Lead Anneke Geyer. We are proud to share our poster presentation: “Nanomechanical Signatures Predict Response to Combination Immunotherapy and Low Dose Radiation Therapy in Advanced Solid Tumors” Presenting Author: Franziska Lisa Lampart Poster Presentation: Saturday, Nov 8  Abstract #584 Join us to learn more about how nanomechanical signature is shaping the future of cancer immunotherapy and improving treatment response prediction. #SITC2025 #Immunotherapy #CancerResearch #OncologyInnovation #ClinicalTrials #Biotech #ARTIDIS Marija Plodinec Marko Loparic Tobias A. Appenzeller Philipp Oertle

“Real hope for improved patient outcomes” It was a true pleasure to welcome Steven Merlin l, Research Patient Advocate and 13-year Stage IV Pancreatic Cancer Survivor, to ARTIDIS in Basel earlier this month. Steven discovered ARTIDIS at the AACR Annual Meeting in Chicago earlier this year and was, in his own words, “immediately intrigued by its potential to transform how solid tumors are understood and treated.”   During his visit, Steven met our team, toured the lab with our Senior Medical Oncologist Carolina Ortiz Velez, and experienced a live demonstration of our technology in action – including a real-time measurement presented by our Product Champion for Pancreas and Lead Scientist of In Vitro Nanotechnology Applications, Reinier Oropesa-Nuñez.    “I’m truly grateful to have met the ARTIDIS team, whose commitment to advancing cancer diagnostics gives real hope for improved patient outcomes”, Steven’s words capture exactly what drives us!    Thank you, Steven, for your visit and your advocacy for patients and innovation in oncology. #PatientAdvocacy #CancerDiagnostics #HealthcareInnovation #AI #Mechanobiology  #AdvocateCollaborative.org  Marija Plodinec Marko Loparic Tobias A. Appenzeller Philipp Oertle Ahmed Jizawi Pancreatic Cancer Action Network Let's Win Pancreatic Cancer American Society of Clinical Oncology (ASCO) American Association for Cancer Research Seena Magowitz Foundation

October may be Breast Cancer Awareness month however, at ARTIDIS, every month is Breast Cancer ACTION month. There is much to be done in improving all aspects of the breast cancer experience and we are actively validating novel ways to improve time to accurate diagnosis and treatment optimization.  Through our ongoing ANGEL study (https://lnkd.in/eBbFTh5e.) at Baylor College of Medicine—supported by leading partners including MD Anderson Cancer Center, Hospital Universitari Vall d'Hebron in Barcelona, St. Claraspital AG in Switzerland, and soon Fred Hutch—we are validating our ability to diagnose breast cancer using nanomechanical phenotyping, delivering accurate results within just a few hours, rather than days. Every study brings us closer to a future where diagnosis is faster, smarter, and more patient-centered—closing the gap between uncertainty and clarity. Because faster, more accurate diagnosis is the first step toward better care. #BreastCancerAwarenessMonth #BreastCancerActionMonth #ARTIDIS #PatientCenteredCare #InnovationInCancerDiagnosis Marija Plodinec Marko Loparic Ahmed Jizawi Tobias A. Appenzeller Philipp Oertle

🚀 𝗪𝗲'𝗿𝗲 𝗛𝗶𝗿𝗶𝗻𝗴 𝗶𝗻 𝗛𝗼𝘂𝘀𝘁𝗼𝗻! 𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗲𝗮𝗺 and Julia Ortega, DMSc, MHS, PA   Join ARTIDIS, a pioneering health-tech startup transforming cancer care with nanomechanical phenotyping. We're looking for a 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝘁𝘂𝗱𝘆 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 to lead and oversee our global clinical trials. If you're passionate about innovation, regulatory excellence, and driving impactful research, this is your chance to make a difference. 🌐 Learn more & apply: Clinical Study Manager at ARTIDIS https://lnkd.in/dJ8JAsmj   If you have strong experience in clinical trial monitoring and site management and would like to join us as a 𝗦𝗲𝗻𝗶𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲, we’d love to hear from you! 🌐 Learn more & apply: Senior CRA at ARTIDIS https://lnkd.in/dJuVXY69 𝗪𝗵𝗮𝘁 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗲𝘅𝗽𝗲𝗰𝘁: • 𝗣𝘂𝗿𝗽𝗼𝘀𝗲𝗳𝘂𝗹 𝘄𝗼𝗿𝗸: Help shape the future of cancer diagnostics and treatment optimization. • 𝗚𝗹𝗼𝗯𝗮𝗹 𝗿𝗲𝗮𝗰𝗵: Contribute to international clinical studies with real-world impact. • 𝗧𝗲𝗮𝗺 𝘀𝗽𝗶𝗿𝗶𝘁: Collaborate with driven experts across clinical, regulatory, and tech.   #ARTIDIS #Hiring #Careers #MedicalTechnology #HealthcareJobs #ClinicalTrials #CRA #Diagnostics #NowHiring #LifeSciences #JoinUs #HoustonJobs #TexasMedicalCenter #TMC #HoustonCareers #HoustonMedTech #WorkInHouston #LifeScienceJobsTX

𝐑𝐞𝐜𝐚𝐩 𝐟𝐫𝐨𝐦 𝐀𝐒𝐓𝐑𝐎 𝖢𝗅𝗂𝗇𝗂𝖼𝗂𝖺𝗇𝗌 𝖺𝗋𝖾 𝖾𝖺𝗀𝖾𝗋 𝖿𝗈𝗋 𝗍𝗈𝗈𝗅𝗌 𝗍𝗁𝖺𝗍 𝗋𝖾𝖽𝗎𝖼𝖾 𝖽𝗂𝖺𝗀𝗇𝗈𝗌𝗍𝗂𝖼 𝗎𝗇𝖼𝖾𝗋𝗍𝖺𝗂𝗇𝗍𝗒 𝖺𝗇𝖽 𝖾𝗆𝗉𝗈𝗐𝖾𝗋 𝗂𝗇𝖽𝗂𝗏𝗂𝖽𝗎𝖺𝗅𝗂𝗓𝖾𝖽 𝖼𝖺𝗋𝖾 𝗉𝗅𝖺𝗇𝗇𝗂𝗇𝗀! 𝖶𝗂𝗍𝗁 𝗍𝗁𝗂𝗌 𝗄𝖾𝗒 𝗍𝖺𝗄𝖾 𝖺𝗐𝖺𝗒 𝗐𝖾 𝖺𝗋𝖾 𝖻𝖺𝖼𝗄 𝖿𝗋𝗈𝗆 𝖠𝖲𝖳𝖱𝖮 𝟤𝟢𝟤𝟧, 𝗐𝗁𝖾𝗋𝖾 𝗍𝗁𝖾 𝖿𝗎𝗍𝗎𝗋𝖾 𝗈𝖿 𝗋𝖺𝖽𝗂𝖺𝗍𝗂𝗈𝗇 𝗈𝗇𝖼𝗈𝗅𝗈𝗀𝗒 𝗍𝖺𝗄𝖾𝗌 𝗌𝗁𝖺𝗉𝖾. 𝖶𝗂𝗍𝗁 𝗈𝗎𝗋 𝖿𝖺𝗇𝗍𝖺𝗌𝗍𝗂𝖼 𝗍𝖾𝖺𝗆 𝗈𝗇-𝗌𝗂𝗍𝖾 Ahmed Jizawi, Jacqueline Tilley, MSc., Papa Diogop Ndiaye, Ana Kalichava, PhD 𝖺𝗇𝖽 𝗍𝗁𝖾 𝗋𝖾𝗌𝗍 𝗈𝖿 𝗎𝗌, 𝗐𝖾 𝗁𝖺𝖽 𝗍𝗁𝖾 𝗈𝗉𝗉𝗈𝗋𝗍𝗎𝗇𝗂𝗍𝗒 𝗍𝗈 𝗅𝖾𝖺𝗋𝗇 𝖿𝗋𝗈𝗆 𝗅𝖾𝖺𝖽𝗂𝗇𝗀 𝖾𝗑𝗉𝖾𝗋𝗍𝗌 𝖺𝗇𝖽 𝖾𝗇𝗀𝖺𝗀𝖾 𝗂𝗇 𝗆𝖾𝖺𝗇𝗂𝗇𝗀𝖿𝗎𝗅 𝖼𝗈𝗇𝗏𝖾𝗋𝗌𝖺𝗍𝗂𝗈𝗇𝗌. 𝖡𝗂𝗀 𝗍𝗁𝖺𝗇𝗄 𝗒𝗈𝗎 𝗍𝗈 𝖾𝗏𝖾𝗋𝗒𝗈𝗇𝖾 𝗐𝗁𝗈 𝗏𝗂𝗌𝗂𝗍𝖾𝖽 𝗎𝗌, 𝗌𝗁𝖺𝗋𝖾𝖽 𝗂𝗇𝗌𝗂𝗀𝗁𝗍𝗌, 𝖺𝗇𝖽 𝖾𝗑𝗉𝗅𝗈𝗋𝖾𝖽 𝗁𝗈𝗐 𝗍𝖾𝖼𝗁𝗇𝗈𝗅𝗈𝗀𝗒 𝖺𝗇𝖽 𝖼𝗈𝗆𝗉𝖺𝗌𝗌𝗂𝗈𝗇 𝖼𝖺𝗇 𝖼𝗈𝗆𝖾 𝗍𝗈𝗀𝖾𝗍𝗁𝖾𝗋 𝗍𝗈 𝗍𝗋𝖺𝗇𝗌𝖿𝗈𝗋𝗆 𝖼𝖺𝗇𝖼𝖾𝗋 𝖼𝖺𝗋𝖾. 𝖠𝖱𝖳𝖨𝖣𝖨𝖲 𝖼𝗈𝗇𝗍𝗂𝗇𝗎𝖾𝗌 𝗍𝗈 𝗌𝗍𝖺𝗇𝖽 𝗈𝗎𝗍 𝖺𝗌 𝖺 𝗀𝖺𝗆𝖾-𝖼𝗁𝖺𝗇𝗀𝗂𝗇𝗀 𝗉𝗅𝖺𝗍𝖿𝗈𝗋𝗆 𝗍𝗈 𝗌𝗎𝗉𝗉𝗈𝗋𝗍 𝗍𝗋𝖾𝖺𝗍𝗆𝖾𝗇𝗍 𝖽𝖾𝖼𝗂𝗌𝗂𝗈𝗇𝗌 𝖿𝗋𝗈𝗆 𝖽𝖺𝗒 𝗈𝗇𝖾. 𝖲𝖾𝖾 𝗒𝗈𝗎 𝗇𝖾𝗑𝗍 𝗒𝖾𝖺𝗋 𝖺𝗍 #𝖠𝖲𝖳𝖱𝖮𝟤𝟢𝟤𝟨! #𝖠𝖲𝖳𝖱𝖮𝟤𝟢𝟤𝟧 #𝖱𝖺𝖽𝗂𝖺𝗍𝗂𝗈𝗇𝖮𝗇𝖼𝗈𝗅𝗈𝗀𝗒 #𝖢𝖺𝗇𝖼𝖾𝗋𝖣𝗂𝖺𝗀𝗇𝗈𝗌𝗍𝗂𝖼𝗌 #ARTIDIS Marija Plodinec Marko Loparic Tobias A. Appenzeller Philipp Oertle